HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Suzanne Ostrand-Rosenberg Selected Research

Histocompatibility Antigens Class II

12/2010Alternative Ii-independent antigen-processing pathway in leukemic blasts involves TAP-dependent peptide loading of HLA class II complexes.
3/2010Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses.
1/2010Uveal melanoma cell-based vaccines express MHC II molecules that traffic via the endocytic and secretory pathways and activate CD8+ cytotoxic, tumor-specific T cells.
5/2007MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells.
2/2006Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines.
1/2004Invariant chain and the MHC class II cytoplasmic domains regulate localization of MHC class II molecules to lipid rafts in tumor cell-based vaccines.
6/2003Intracytoplasmic domains of MHC class II molecules are essential for lipid-raft-dependent signaling.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Suzanne Ostrand-Rosenberg Research Topics

Disease

64Neoplasms (Cancer)
01/2021 - 08/2002
12Inflammation (Inflammations)
01/2018 - 01/2006
10Carcinoma (Carcinomatosis)
01/2017 - 08/2002
4Melanoma (Melanoma, Malignant)
10/2015 - 03/2004
3Neoplasm Metastasis (Metastasis)
01/2021 - 09/2009
3Sarcoma (Soft Tissue Sarcoma)
10/2015 - 06/2003
3Breast Neoplasms (Breast Cancer)
10/2015 - 01/2006
2Bites and Stings (Sting)
01/2019 - 08/2017
2Obesity
01/2018 - 01/2018
2Lung Neoplasms (Lung Cancer)
12/2010 - 10/2008
2Uveal melanoma
01/2010 - 05/2007
1Hypoxia (Hypoxemia)
02/2020
1Acquired Immunodeficiency Syndrome (AIDS)
01/2020
1Tuberculosis (Tuberculoses)
01/2020
1Infections
01/2019
1Insulin Resistance
07/2011
1Large Cell Carcinoma
12/2010
1Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
12/2010
1Leukemia
12/2010
1Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
03/2010

Drug/Important Bio-Agent (IBA)

14VaccinesIBA
10/2015 - 01/2004
11Proteins (Proteins, Gene)FDA Link
01/2018 - 10/2008
10invariant chain (Ii-Key)IBA
10/2015 - 01/2004
9Peptides (Polypeptides)IBA
01/2016 - 03/2004
7Histocompatibility Antigens Class IIIBA
12/2010 - 06/2003
6Neoplasm Antigens (Tumor Antigens)IBA
11/2012 - 01/2004
5CytokinesIBA
12/2014 - 08/2002
5HLA-DR Antigens (HLA-DR)IBA
11/2012 - 03/2004
5Cancer VaccinesIBA
03/2008 - 01/2004
4AntigensIBA
08/2017 - 03/2004
4Interleukin-6 (Interleukin 6)IBA
12/2014 - 10/2007
4Interleukin-10 (Interleukin 10)IBA
12/2014 - 07/2007
3Interleukin-12 (IL 12)IBA
12/2014 - 07/2007
3EpitopesIBA
02/2006 - 06/2004
2HMGB1 Protein (HMG1)IBA
02/2020 - 10/2014
2LeptinIBA
01/2018 - 01/2018
2L-SelectinIBA
12/2016 - 07/2009
2B7-H1 AntigenIBA
10/2014 - 06/2011
2LigandsIBA
09/2013 - 06/2011
2MHC class II transactivator proteinIBA
11/2012 - 01/2006
2InterleukinsIBA
08/2012 - 10/2007
2Interferon-gamma (Interferon, gamma)IBA
09/2009 - 08/2002
2Small Interfering RNA (siRNA)IBA
09/2009 - 01/2006
2ArginaseIBA
10/2008 - 12/2005
2Interleukin-13IBA
12/2005 - 11/2002
2LipidsIBA
01/2004 - 06/2003
1Receptor for Advanced Glycation End ProductsIBA
01/2021
1Reactive Oxygen Species (Oxygen Radicals)IBA
02/2020
1Oxygen (Dioxygen)IBA
02/2020
1Transcription Factors (Transcription Factor)IBA
02/2020
1Fatty Acids (Saturated Fatty Acids)IBA
01/2018
1UbiquitinIBA
01/2018
1AdipokinesIBA
01/2018
1Ubiquitinated ProteinsIBA
01/2018
1Glycoproteins (Glycoprotein)IBA
01/2017
1Programmed Cell Death 1 ReceptorIBA
10/2015
1AntibodiesIBA
10/2015
1ProteomeIBA
02/2014
1withaferin AIBA
11/2013
1AshwagandhaIBA
11/2013
1Immunoglobulin G (IgG)IBA
09/2013
1HLA-DR7 Antigen (HLA DR7 Antigen)IBA
11/2012
1Indicators and Reagents (Reagents)IBA
11/2012
1Biological ProductsIBA
08/2012
1EnzymesIBA
08/2012
1Indoleamine-Pyrrole 2,3,-Dioxygenase (Indoleamine 2,3 Dioxygenase)IBA
08/2012
1p38 Mitogen-Activated Protein KinasesIBA
08/2012
1Enzyme Inhibitors (Inhibitors, Enzyme)IBA
08/2012
1Glucose (Dextrose)FDA LinkGeneric
07/2011
1Caspase 3 (Caspase-3)IBA
03/2011
1CaspasesIBA
03/2011
1Caspase 8 (Caspase-8)IBA
03/2011
1Proteasome Endopeptidase Complex (Proteasome)IBA
12/2010
1HLA-A Antigens (HLA-A)IBA
01/2010
1Cyclooxygenase 2 (Cyclooxygenase-2)IBA
09/2009
1Prostaglandin E Receptors (Prostaglandin E Receptor)IBA
09/2009
1AH 23848IBA
09/2009
1Urokinase-Type Plasminogen Activator (Urokinase)FDA Link
07/2009
1Plasminogen Activators (Plasminogen Activator)IBA
07/2009
1Toll-Like Receptor 4IBA
06/2009
1Complement System Proteins (Complement)IBA
12/2008
1Prostaglandins EIBA
10/2008
1NF-kappa B (NF-kB)IBA
10/2008
1Polysaccharides (Glycans)IBA
10/2008
1Interleukin-1 Receptors (Interleukin 1 Receptor)IBA
10/2007
1GemcitabineFDA Link
07/2007
1Interleukin-1beta (Interleukin 1 beta)IBA
05/2007
1Dinoprostone (PGE2)FDA Link
05/2007
14- (5- (4- chlorophenyl)- 3- (trifluoromethyl)- 1H- pyrazol- 1- yl)benzenesulfonamideIBA
05/2007
1Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA
05/2007
1Histocompatibility Antigens Class IIBA
02/2006
1alpha-galactosylceramideIBA
12/2005
1Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA
12/2005
1Nitric Oxide (Nitrogen Monoxide)FDA Link
11/2005

Therapy/Procedure

22Immunotherapy
01/2019 - 01/2004
8Therapeutics
01/2020 - 01/2004
2Transplantation
01/2019 - 04/2004
2Surgical Instruments (Clip)
12/2010 - 03/2010
1Radiotherapy
01/2019
1Fat-Restricted Diet (Diet, Fat Restricted)
01/2018